ALLY-1 trial results show daclatasvir-based regimen cures 94% of post-liver transplants
Bristol-Myers Squibb were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily with ribavirin for treatment of patients with chronic HCV with either advanced cirrhosis or post-liver transplant recurrence of HCV. April 25, 2015